CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s
This article was originally published in The Pink Sheet Daily
Executive Summary
Broad nature of latest cholesterol treatment guidelines makes it hard to deploy utilization management programs to control use of pricey new PCSK9 inhibitors, CVS Health argues in JAMA editorial.